MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Botulinum Toxin-A for Hidradenitis Suppurativa

Phase 4
Not yet recruiting
Conditions
Hidradenitis Suppurativa
Hidradenitis Suppurativa, Acne Inversa
Hidradenitis Suppurativa \(HS\)
Interventions
Drug: Normal saline
First Posted Date
2024-02-01
Last Posted Date
2024-12-06
Lead Sponsor
Yale University
Target Recruit Count
30
Registration Number
NCT06237465
Locations
🇺🇸

Yale Medicine Multispecialty Clinic, Guilford, Connecticut, United States

Repetitive Transcranial Magnetic Stimulation Versus Botulinum Injection on Spasticity on Children With Diplegic Cerebral Palsy

Not Applicable
Conditions
Spastic Diplegic Cerebral Palsy
Interventions
Device: Transcranial Magnetic Stimulation
Other: Rehabilitation Training Protocol
First Posted Date
2024-01-23
Last Posted Date
2024-07-03
Lead Sponsor
MTI University
Target Recruit Count
75
Registration Number
NCT06218316
Locations
🇪🇬

faculty of pysical therapy, MTI university, Cairo, Egypt

OnabotulinumtoxinA for Trigeminal Neuralgia

Phase 4
Recruiting
Conditions
Trigeminal Neuralgia
Interventions
Drug: Sodium Chloride 0.9% for Injection, Preservative Free
First Posted Date
2024-01-22
Last Posted Date
2025-01-28
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT06216886
Locations
🇺🇸

Meredith Barad, Stanford, California, United States

Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal Achalasia

Not Applicable
Recruiting
Conditions
Cricopharyngeal Achalasia
Dysphagia
Interventions
First Posted Date
2024-01-19
Last Posted Date
2024-05-16
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
20
Registration Number
NCT06213662
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Migraine Medication Effects on Urinary Symptoms

Conditions
Bladder Pain Syndrome
Migraine Disorders
Migraine
Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor
Interstitial Cystitis
Interventions
First Posted Date
2024-01-19
Last Posted Date
2024-05-16
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
200
Registration Number
NCT06212661
Locations
🇺🇸

Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Phase 3
Recruiting
Conditions
Glabellar Lines
Interventions
First Posted Date
2024-01-16
Last Posted Date
2024-10-03
Lead Sponsor
Huons Biopharma
Target Recruit Count
312
Registration Number
NCT06205797
Locations
🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction

Not Applicable
Recruiting
Conditions
Dysphagia, Oropharyngeal
Dysphagia, Esophageal
Brain Stem Infarctions
Interventions
First Posted Date
2024-01-09
Last Posted Date
2024-05-14
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Target Recruit Count
20
Registration Number
NCT06196606
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy

Phase 3
Not yet recruiting
Conditions
Spasticity/Paresis
Cerebral Palsy
Interventions
Device: ESWT
Other: Serial Casting
Behavioral: Physical Therapy
Behavioral: Occupational Therapy
First Posted Date
2023-11-13
Last Posted Date
2023-11-18
Lead Sponsor
Kocaeli University
Target Recruit Count
40
Registration Number
NCT06128616

Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.

Not Applicable
Not yet recruiting
Conditions
Freezing of Gate
Parkinson Disease
Botulinum Toxin
Interventions
First Posted Date
2023-10-23
Last Posted Date
2023-10-23
Lead Sponsor
Centro Hospitalar de Lisboa Central
Target Recruit Count
20
Registration Number
NCT06094309
Locations
🇵🇹

Maria Margarida Grilo da Silva Dias, Lisboa, Portugal

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

Phase 2
Active, not recruiting
Conditions
Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
Interventions
First Posted Date
2023-10-19
Last Posted Date
2025-04-23
Lead Sponsor
Merz Therapeutics GmbH
Target Recruit Count
123
Registration Number
NCT06091020
Locations
🇧🇬

Merz Investigational Site #3590004, Plovdiv, Bulgaria

🇧🇬

Merz Investigational Site #3590006, Sofia, Bulgaria

🇧🇬

Merz Investigational Site #3590005, Sofia, Bulgaria

and more 28 locations
© Copyright 2025. All Rights Reserved by MedPath